FrancophonIA/ELRC3.0 huggingface dataset:
English: • bosentan, used to treat pulmonary arterial hypertension
Slovenian: • bosentan, uporablja se za zdravljenje pljučne arterijske hipertenzije
English: • Do not give this medicine to children and adolescents under 18 years of age.
Slovenian: • Otrokom in mladostnikom, starim manj kot 18 let, ne dajajte tega zdravila.
English: No data are available on which to make a dose recommendation for patients over the age of 65 years
Slovenian: Podatkov, na osnovi katerih bi lahko priporočili odmerke za bolnike, starejše od 65 let, ni na voljo
English: • If you have liver problems or a history of liver disease, including hepatitis.
Slovenian: • Če imate težave z jetri ali ste kdaj imeli jetrno bolezen, vključno s hepatitisom.
English: c Includes patients who discontinued due to an AE or death at any time point from day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
Slovenian: c Vključuje bolnike, ki so prenehali sodelovati zaradi neželenih učinkov ali smrti, kadar koli od 1. dne do konca časovnega okna, če zaradi tega v določenem oknu ni bilo viroloških podatkov o zdravljenju.
English: This will improve your immune system and reduce the risk of developing illnesses linked to
Slovenian: S tem se vaš imunski sistem izboljša in zmanjša se tveganje za razvoj bolezni,
English: Contains lactose, see leaflet for further information.
Slovenian: Vsebuje laktozo, za dodatne informacije glejte navodilo za uporabo.
English: Table 2: Interactions between elvitegravir and other medicinal products
Slovenian: Preglednica 2: Interakcije med elvitegravirjem in drugimi zdravili
English: • Women must not get pregnant while taking Vitekta.
Slovenian: • Ženske ne smejo zanositi, medtem ko se zdravijo z zdravilom Vitekta.
English: d Includes subjects who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g., withdrew consent,
Slovenian: d Vključuje osebe, ki so sodelovanje prekinile zaradi razlogov, ki niso bili neželeni učinki, smrt ali pomanjkanje ali izguba učinka, npr. umik soglasja, izgubljeni za spremljanje itd.
English: If overdose occurs the patient must be monitored for evidence of toxicity.
Slovenian: V primeru prevelikega odmerka je potrebno bolnika nadzorovati glede znakov toksičnosti.
English: When treating HIV infection, it is not always possible to tell whether some of the unwanted effects are caused by Vitekta or by other medicines that you are taking at the same time, or by the HIV infection
Slovenian: Pri zdravljenju okužbe z virusom HIV ni vedno mogoče povedati, ali nekatere od naštetih neželenih učinkov povzroča zdravilo Vitekta ali druga zdravila, ki jih jemljete sočasno, ali sama okužba s HIV.
English: Other medicines used in treating HIV infection: You should not take Vitekta with other medicines containing:
Slovenian: Druga zdravila, ki se uporabljajo za zdravljenje okužbe s HIV: Zdravila Vitekta ne jemljite z drugimi zdravili, ki vsebujejo:
English: Frequencies are defined as common (≥ 1/100 to < 1/10) or
Slovenian: Pogostnost je definirana kot pogosti (≥ 1/100 do < 1/10) ali občasni (≥ 1/1.000 do < 1/100).
English: Further increases in ritonavir dose do not result in further increases in elvitegravir exposure.
Slovenian: Nadaljna povečanja odmerka ritonavirja niso povzročila nadaljnjih povečanj izpostavljenosti elvitegravirju.
English: The frequency of this is unknown
Slovenian: Pogostnost tega ni znana (glejte
English: Vitekta may interact with other medicines which can affect the amounts of Vitekta or other medicines in your blood.
Slovenian: Zdravilo Vitekta lahko medsebojno deluje z drugimi zdravili, kar lahko vpliva na količino zdravila Vitekta ali drugih zdravil v vaši krvi.
English: Vitekta stops this enzyme working and reduces the amount of HIV in your body.
Slovenian: Zdravilo Vitekta ustavi delovanje tega encima in zmanjša količino virusa HIV v vašem telesu.
English: Do not breast-feed during treatment with Vitekta: It is not known if the active substance in this medicine can pass into human breast milk.
Slovenian: Med zdravljenjem z zdravilom Vitekta ne dojite: Ni znano, ali lahko zdravilna učinkovina tega zdravila prehaja v materino mleko.
English: However, the maximum exposures evaluated in the rabbit were not in excess of those achieved therapeutically (see section 5.3).
Slovenian: Vendar pa največje izpostavljenosti, ki so jih ocenili pri kuncih, niso presegale terapevtsko doseženih izpostavljenosti (glejte poglavje 5.3).
English: Pharmacokinetics of elvitegravir have not been fully evaluated in the elderly (over 65 years of age).
Slovenian: Farmakokinetičnih lastnosti elvitegravirja pri starejših (starih nad 65 let) niso v celoti ovrednotili.
English: The mean plasma to blood drug concentration ratio is 1.37.
Slovenian: Povprečno razmerje med koncentracijo zdravila v plazmi in krvi je bilo 1,37.
English: In treatment-experienced HIV-1 infected patients
Slovenian: Pri predhodno zdravljenih bolnikih, okuženih s HIV-1
English: If you are lactose-intolerant, or if you have been told that you have an intolerance to other sugars, talk to your doctor before taking this medicine.
Slovenian: Če ne prenašate laktoze ali so vam povedali, da ne prenašate drugih sladkorjev, se pred uporabo tega zdravila posvetujete z zdravnikom.
English: • antacids, used to treat heartburn or acid reflux, such as aluminium/magnesium hydroxide or calcium carbonate (see also section 3 of this leaflet)
Slovenian: • antacide,uporabljajo se za zdravljenje zgage ali refluksa kisline, kot so aluminijev/magnezijev hidroksid ali kalcijev karbonat (glejte tudi poglavje 3 tega navodila)
English: These interactions are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious adverse events or loss of therapeutic effect.
Slovenian: Opisane interakcije temeljijo bodisi na študijah interakcij zdravila ali na interakcijah, napovedanih na podlagi pričakovanega obsega interakcij in možnih resnih neželenih učinkov ali izgube terapevtskega
English: As the effect of cationic complexation of elvitegravir cannot be excluded when co-administered with multivitamin supplements, it is recommended to separate Vitekta and multivitamin supplements dosing by at least 4 hours.
Slovenian: Ker učinka kationske kompleksacije elvitegravirja pri sočasni uporabi z multivitaminskimi dopolnili ni mogoče izključiti, se priporoča, da se dajanje zdravila Vitekta in multivitaminskih dopolnil loči za vsaj 4 ure.
English: Of these 712 patients, 543 (269 elvitegravir and 274 raltegravir) and 439 (224 elvitegravir and 215 raltegravir) received at least 48 and 96 weeks of treatment, respectively.
Slovenian: Med temi 712 bolniki jih je 543 (269 elvitegravir in 274 raltegravir) prejemalo vsaj 48 tednov in 439 (224 elvitegravir in 215 raltegravir) vsaj 96 tednov zdravljenja.
English: Discontinued study drug due to AE or death c
Slovenian: študijskega zdravila zaradi neželenega učinka ali smrti c
English: The pharmacokinetic parameters of the protease inhibitors presented in Table 2 were assessed in the presence of ritonavir.
Slovenian: Parametre farmakokinetike zaviralcev proteaze, predstavljenih v preglednici 2, so ocenili v prisotnosti ritonavirja.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with elvitegravir in one or more subsets of the paediatric population in the treatment of HIV-1 infection (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z elvitegravirjem za eno ali več podskupin pediatrične populacije za zdravljenje okužbe s HIV-1 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Vitekta should be taken orally, once daily with food (see section 5.2).
Slovenian: Zdravilo Vitekta se jemlje enkrat dnevno, peroralno s hrano (glejte poglavje 5.2).
English: If you have advanced HIV infection (AIDS) and have an infection, you may develop symptoms of infection and inflammation or worsening of the symptoms of an existing infection once treatment with Vitekta is started.
Slovenian: Če imate napredovalo okužbo s HIV (AIDS) in okužbo, se lahko razvijejo simptomi okužbe in vnetja ali pa se simptomi obstoječe okužbe poslabšajo, ko se začne zdravljenje z zdravilom Vitekta.
English: Available pharmacodynamic/toxicological data in rats have shown excretion of elvitegravir in milk.
Slovenian: Razpoložljivi farmakodinamični/toksikološki podatki pri podganah kažejo na izločanje elvitegravirja v mleko.
English: Interactions between elvitegravir and potential co-administered medicinal products are listed in Table 2 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”).
Slovenian: Interakcije med elvitegravirjem in možnimi sočasno uporabljenimi zdravili so navedene v preglednici 2 spodaj (povečanje je označeno z znakom "↑", zmanjšanje z "↓", brez spremembe z "↔").
English: If you are also taking an antacid such as aluminium/magnesium hydroxide or calcium carbonate, or a multivitamin supplement, take it at least 4 hours before or at least 4 hours after Vitekta.
Slovenian: Če jemljete tudi antacid, kot je aluminijev/magnezijev hidroksid ali kalcijev karbonat ali multivitaminsko dopolnilo, ga vzamite vsaj 4 ure pred uporabo zdravila Vitekta ali najmanj 4 ure po
English: In these subjects, diarrhoea was mild to moderate in severity and did not result in discontinuation of study drug.
Slovenian: Pri teh osebah je bila driska blaga do zmerna in ni povzročila prekinitve uporabe študijskega zdravila.
English: HIV-1 RNA < 50 copies/mL, n/N (%)
Slovenian: HIV-1 RNA < 50 kopij/ml, n/N (%)
English: Elvitegravir versus raltegravir
Slovenian: Elvitegravir v primerjavi z raltegravirjem
English: Medicinal products that are strong (causing a > 5-fold increase in substrate clearance) or moderate (causing a 2-5 fold increase in substrate clearance) inducers of CYP3A are expected to decrease plasma concentrations of elvitegravir.
Slovenian: Za zdravila, ki so močni (povzročijo > 5-kratno zvišanje očistka substrata) ali zmerni (povzročijo 2-5-kratno zvišanje očistka substrata) induktorji CYP3A, se pričakuje, da bodo zmanjševali koncentracije elvitegravirja v plazmi.
English: Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
Slovenian: Pri nekaterih bolnikih, ki jemljejo kombinirano protiretrovirusno terapijo, se lahko pojavi bolezen kosti, imenovana osteonekroza (odmiranje kostnega tkiva kot posledica pomanjkanja oskrbe kosti s krvjo).
English: Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the viral infection.
Slovenian: Zaviranje integraze preprečuje integracijo DNA virusa HIV-1 v genomsko DNA gostitelja in prepreči nastanek provirusa HIV-1 ter širjenje virusne okužbe.
English: Although there may be no actual or predicted interactions between a medicinal product and elvitegravir, there may be interactions between a medicinal product and ritonavir and/or the protease inhibitor co-administered with elvitegravir.
Slovenian: Čeprav morda ni dejanskih ali predvidenih interakcij med zdravilom in elvitegravirjem, lahko nastopijo interakcije med zdravilom in ritonavirjem in/ali zaviralcem proteaze, uporabljenem sočasno z elvitegravirjem.
English: As such, elvitegravir may decrease the plasma concentration of substrates of CYP2C9 (such as warfarin) or UGT (such as ethinyl estradiol).
Slovenian: Kot tak lahko elvitegravir zmanjša koncentracije substratov CYP2C9 (kot je varfarin) ali UGT (kot je etinilestradiol) v plazmi.
English: The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease.
Slovenian: Dolgotrajno kombinirano protiretrovirusno zdravljenje, uporaba kortikosteroidov, pitje alkohola, močno zavrt imunski sistem in višji indeks telesne mase so lahko nekateri od številnih dejavnikov tveganja za nastanek te bolezni.
English: Randomisation was stratified by screening HIV-1 RNA level (≤ 100,000 copies/mL or > 100,000 copies/mL) and the class of the second agent (NRTI or other classes).
Slovenian: Randomizacija je bila stratificirana s presejanjem ravni HIV-1 RNA (≤ 100.000 kopij/ml ali > 100.000 kopij/ml) in razred drugega zdravila (NRTI ali drugi razredi).
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product
Slovenian: B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le s posebnim režimom (glejte Prilogo I: Povzetek glavnih
English: Elvitegravir is 98-99% bound to human plasma proteins and the binding is independent of drug concentration over the range of 1.0 ng/mL to 1.6 µg/mL.
Slovenian: Elvitegravir se 98-99 % veže na humane plazemske proteine, pri čemer vezava ni odvisna od koncentracije zdravila v razponu od 1,0 ng/ml do 1,6 µg/ml.
English: Additional integrase substitutions observed in cell culture selection included H51Y, F121Y, S147G, S153Y, E157Q, and R263K.
Slovenian: Dodatne substitucije integraze, ki so jih opazili v izboru celične kulture, so vključevale H51Y, F121Y, S147G, S153Y, E157Q in R263K.
English: Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice.
Slovenian: Bolniki z že obstoječo jetrno disfunkcijo, vključno s kroničnim aktivnim hepatitisom, imajo v času kombinirane protiretrovirusne terapije (combination antiretroviral therapy, CART) več anomalij jetrne funkcije in jih je treba nadzirati v skladu s standardno prakso.
English: Where interactions were studied, the effect on Vitekta was determined by comparing the pharmacokinetics of boosted elvitegravir (using either ritonavir or cobicistat as a pharmacokinetic enhancer) in the absence and presence of the co-administered medicinal product.
Slovenian: Kjer so interakcije preučili, so učinke na zdravilo Vitekta določili s primerjavo farmakokinetike ojačanega elvitegravirja (z uporabo ritonavirja ali kobicistata kot farmakokinetičnega ojačevalca) v odsotnosti in prisotnosti sočasno uporabljenega zdravila.
English: Vitekta is a treatment for human immunodeficiency virus (HIV) infection in adults aged 18 years
Slovenian: Zdravilo Vitekta je zdravilo za zdravljenje okužbe z virusom imunske pomanjkljivosti pri človeku (HIV, human immunodeficiency virus) pri odraslih, starih 18 let in več.
English: C]elvitegravir, 94.8% of the dose was recovered in faeces, consistent with the hepatobiliary elimination of elvitegravir; 6.7% of the administered dose was recovered in urine as metabolites.
Slovenian: C]elvitegravirja so 94,8 % odmerka izolirali iz blata, kar je v skladu s hepatobiliarnim izločanjem elvitegravirja; 6,7 % danega odmerka so izolirali iz urina v obliki presnovkov.
English: Similar rates of raltegravir resistance development occurred in the HIV-1 from subjects treated with raltegravir (26/351 raltegravir-treated subjects, 7.4%).
Slovenian: Podobne stopnje razvoja rezistence na raltegravir so se pojavile v izolatih HIV-1 pri osebah, zdravljenih z raltegravirjem (26/351 oseb, zdravljenih z raltegravirjem, 7,4 %).
English: High density polyethylene (HDPE) bottle with a child-resistant closure containing 30 film-coated
Slovenian: Plastenka iz polietilena visoke gostote (HDPE), z za otroke varno zaporko, ki vsebuje 30 filmsko
English: Do not stop taking Vitekta without talking to your doctor.
Slovenian: Ne prenehajte jemati zdravila Vitekta, ne da bi se posvetovali s svojim zdravnikom.
English: Patients using oestrogens as hormone replacement therapy should be clinically monitored for signs of oestrogen deficiency (see section 4.5).
Slovenian: Bolnice, ki uporabljajo estrogen kot nadomestno hormonsko terapijo, je treba klinično spremljati za znake pomanjkanja estrogena (glejte poglavje 4.5).
English: The BR was selected by the investigator based on genotypic/phenotypic resistance testing and prior antiretroviral treatment history.
Slovenian: Osnovni režim je izbral raziskovalec na podlagi genotipskega/fenotipskega testiranja rezistence in zdravljenja s protiretrovirusnimi zdravili.
English: Viruses expressing the T66I/A substitutions maintain susceptibility to raltegravir, while most other patterns of elvitegravir-associated substitutions are associated with reduced susceptibility to raltegravir.
Slovenian: Virusi, ki izražajo substitucije T66I/A, ostanejo občutljivi na raltegravir, medtem ko je večina drugih vzorcev substitucij, povezanih z elvitegravirjem, povezana z zmanjšano občutljivostjo na raltegravir.
English: Vitekta should not be used during pregnancy unless the clinical condition of the woman requires treatment with elvitegravir.
Slovenian: Zdravila Vitekta ne smete uporabljati pri nosečnicah, razen če klinično stanje nosečnice zahteva zdravljenje z elvitegravirjem.
English: What Vitekta is and what it is used for What you need to know before you take Vitekta
Slovenian: Kaj je zdravilo Vitekta in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Vitekta
English:  If any of these applies to you, do not take Vitekta and tell your doctor immediately.
Slovenian:  Če kar koli od tega velja za vas, ne jemljite zdravila Vitekta in o tem nemudoma obvestite svojega zdravnika.
English:  If you notice any of these symptoms, tell your doctor immediately.
Slovenian:  Če opazite katerega od teh simptomov, takoj obvestite svojega zdravnika.
English: If you vomit less than 1 hour after taking Vitekta, take another tablet with food.
Slovenian: Če bruhate manj kot 1 uro po zaužitju zdravila Vitekta, vzemite še eno tableto s hrano.
English: The frequency of the following side effects is not known (frequency cannot be estimated from the
Slovenian: Drugi možni učinki pri zdravljenju HIV Pogostnost naslednjih neželenih učinkov je neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
English: If you are a woman with HIV it is recommended that you do not breast-feed to avoid passing the virus to the baby in breast milk.
Slovenian: Če ste ženska, okužena z virusom HIV, je priporočljivo, da ne dojite, da s tem preprečite prenos virusa na dojenčka preko mleka.
English: The absolute oral bioavailability has not been
Slovenian: Absolutne peroralne biološke uporabnosti niso določili.
English: Co-administration with the following medicinal products due to the potential for loss of virologic response and possible development of resistance (see section 4.5):
Slovenian: Sočasno dajanje z naslednjimi zdravili zaradi možne izgube virološkega odziva in možnega razvoja rezistence (glejte poglavje 4.5):
English: Interactions with CYP3A inducers
Slovenian: Medsebojno delovanje z induktorji CYP3A
English: With the exception of Y143C/R/H, HIV-1 with the primary raltegravir-associated substitutions T66K, Q148H/K/R, or N155H in integrase is associated with reduced susceptibility to elvitegravir.
Slovenian: Z izjemo Y143C/R/H je HIV-1 s primarnimi z raltegravirjem povezanimi substitucijami T66K, Q148H/K/R ali N155H v integrazi povezan z zmanjšano občutljivostjo na elvitegravir.
English: Vitekta should not be used with a protease inhibitor boosted by another agent as dosing recommendations for such combinations have not been established.
Slovenian: Zdravila Vitekta se ne sme uporabljati z zaviralcem proteaze, ojačanim z drugim zdravilom, saj priporočil za uporabo te kombinacije še niso določili.
English: The active substance elvitegravir is persistent in the environment.
Slovenian: Zdravilna učinkovina elvitegravir je v okolju obstojna.
English: What you need to know before you take Vitekta Do not take Vitekta
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Vitekta Ne jemljite zdravila Vitekta
English: Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia.
Slovenian: Primeri teh reakcij so citomegalovirusni retinitis, generalizirane in/ali žariščne okužbe z mikobakterijami in s Pneumocystis jirovecii povzročena pljučnica.
English: It is important not to miss a dose of Vitekta.
Slovenian: Pomembno je, da ne pozabite vzeti nobenega odmerka zdravila Vitekta.
English: If you notice signs of inflammation or infection, tell your doctor at once.
Slovenian: Če opazite znake vnetij ali okužb, to takoj povejte zdravniku.
English: Except where indicated in Table 2, the dose of boosted elvitegravir or co-administered medicinal product was the same when administered alone or in combination.
Slovenian: Razen kjer je navedeno v preglednici 2, so bili odmerki ojačanega elvitegravirja ali sočasno uporabljenega zdravila enaki pri dajanju zdravila samega ali v kombinaciji.
English: If you take more Vitekta than you should
Slovenian: Če ste vzeli večji odmerek zdravila Vitekta, kot bi smeli
English: Phenotypic resistance to elvitegravir was most commonly associated with the primary integrase substitutions T66I, E92Q and Q148R.
Slovenian: Fenotipska rezistenca na elvitegravir je bila najbolj pogosto povezana s primarnimi substitucijami integraze T66I, E92Q in Q148R.
English: Metabolic parameters
Slovenian: Presnovni parametric
English: C]elvitegravir, elvitegravir was the predominant species in plasma, representing approximately 94% and 61% of the circulating radioactivity at 32 and 48 hours, respectively.
Slovenian: C]elvitegravirja je bil elvitegravir prevladujoča vrsta v plazmi in je po 32 urah predstavljal približno 94 % in po 48 urah približno 61 % cirkulirajoče radioaktivnosti.
English: Integrase is an HIV-1 encoded enzyme that is required for viral replication.
Slovenian: Integraza je encim, ki ga kodira HIV-1 in je potreben za razmnoževanje virusa.
English: Elvitegravir did not show inhibition of replication of HBV or HCV in vitro.
Slovenian: Elvitegravir in vitro ni kazal zaviranja replikacije HBV ali HCV.
English: Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART.
Slovenian: Čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV in/ali dolgotrajno izpostavljenostjo CART.
English: If Vitekta is stopped for any reason, speak to your doctor before you restart taking Vitekta tablets.
Slovenian: Če zaradi katerega koli razloga prenehate jemati zdravilo Vitekta, se pogovorite s svojim zdravnikom, preden začnete ponovno jemati tablete zdravila Vitekta.
English: Elvitegravir would also have potential to be a weak to modest inducer of CYP2B6 and CYP2C8 enzymes, as these enzymes are regulated in a similar manner to CYP2C9 and CYP3A.
Slovenian: Elvitegravir je lahko tudi šibek ali zmeren induktor encimov CYP2B6 in CYP2C8, saj se ti encimi uravnavajo na podoben način kot CYP2C9 in CYP3A.
English: If a patient misses a dose of Vitekta by more than 18 hours, and it is almost time for their next dose, the patient should not take the missed dose and simply resume the usual dosing schedule.
Slovenian: Če bolnik izpusti odmerek zdravila Vitekta za več kot 18 ur, in je že skoraj čas za njegov naslednji odmerek, naj bolnik ne nadomesti izpuščenega odmerka in preprosto nadaljuje z jemanjem
English: Elvitegravir is a substrate for OATP1B1 and OATP1B3, and an inhibitor of OATP1B3 in vitro.
Slovenian: Elvitegravir je substrat za OATP1B1 in OATP1B3 in in vitro zaviralec OATP1B3.
English: Co-administration of Vitekta and rifabutin is not recommended.
Slovenian: Sočasno dajanje zdravila Vitekta in rifabutina se ne priporoča.